4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Return on Capital Employed came in at 36.17% in Q1 2026, up 361.0% year-on-year from 7.85% in Q1 2025, and down 2.32% on a QoQ basis from 35.35% in Q4 2025.
4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 6 years of Return on Capital Employed data on file, last reported at 36.17% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 361.0% year-over-year to 36.17% in Q1 2026; TTM through Mar 2026 was 36.17%, a 361.0% increase from a year earlier, with the FY2025 full-year figure at 30.71%, up 1391.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 36.17%, down from 35.35% in the prior quarter.
- Over the last five years, Return on Capital Employed for FDMT reached as high as 21.67% in Q2 2024 and fell as low as 55.96% in Q3 2025.
- Historically, Return on Capital Employed has averaged 36.42% across 5 years, with a median of 35.35% in 2025.
- Across the five-year window, Return on Capital Employed soared 2126 bps in 2024 and sank 2706 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 43.1% in 2022, then grew by 21 bps to 34.02% in 2023, then advanced by 0 bps to 33.96% in 2024, then decreased by 4 bps to 35.35% in 2025, then dropped by 2 bps to 36.17% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 36.17% in Q1 2026, 35.35% in Q4 2025, and 55.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -36.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.17% |
| Dec 31, 2025 | -35.35% |
| Sep 30, 2025 | -55.96% |
| Jun 30, 2025 | -47.90% |
| Mar 31, 2025 | -39.78% |
| Dec 31, 2024 | -33.96% |
| Sep 30, 2024 | -28.90% |
| Jun 30, 2024 | -21.67% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -34.02% |
| Sep 30, 2023 | -30.96% |
| Jun 30, 2023 | -41.28% |
| Mar 31, 2023 | -47.07% |
| Dec 31, 2022 | -43.10% |
| Sep 30, 2022 | -38.16% |
| Jun 30, 2022 | -34.13% |
| Mar 31, 2022 | -24.89% |
| Dec 31, 2021 | -25.41% |
| Sep 30, 2021 | -28.34% |
| Jun 30, 2021 | -20.64% |